NCT05544552: Safety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors With FGFR3 Gene Alterations
- State
- Under way
- Phase
- Phase 1 and Phase 2
- People
- 310 planned
- Started
- 22 Nov 2022
- Primary completion
- Nov 2026
- Arms
- Phase 1 Part A - dose escalation, Phase 1 Part B - dose expansion, Phase 2
- Results
- None posted
- 16 Sep 2022: Trial registered
- 22 Nov 2022: Trial started